Craneware PLC
LSE:CRW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (14.8), the stock would be worth GBX2 119.45 (36% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11 | GBX1 564 |
0%
|
| 3-Year Average | 14.8 | GBX2 119.45 |
+36%
|
| 5-Year Average | 16.3 | GBX2 326.08 |
+49%
|
| Industry Average | 0 | GBX3.46 |
-100%
|
| Country Average | 0 | GBX2.81 |
-100%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
GBX479.2m
|
/ |
Jan 2026
$64.6m
|
= |
|
|
GBX479.2m
|
/ |
Jun 2026
$72.8m
|
= |
|
|
GBX479.2m
|
/ |
Jun 2027
$80.1m
|
= |
|
|
GBX479.2m
|
/ |
Jun 2028
$86.8m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Craneware PLC
LSE:CRW
|
553.8m GBP | 11 | 31.6 | |
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD | 21.9 | 53.1 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
25.6B USD | 19.1 | 28.1 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
14.8B AUD | 76.7 | 61.9 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 9.8 | 20.2 | |
| SE |
|
Sectra AB
STO:SECT B
|
52.1B SEK | -134.4 | 97 | |
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.8B USD | 15 | 41.5 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
4.3B USD | 14.1 | 17.9 | |
| US |
H
|
Heartflow Inc
NASDAQ:HTFL
|
2.7B USD | 0 | 0 | |
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
19.3B CNY | -122.4 | -62.7 | |
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR | 267.9 | -328 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Craneware PLC
Glance View
Craneware PLC, a prominent player in the healthcare software industry, crafts its narrative in the pursuit of financial optimization for hospitals across the United States. Established in 1999, Craneware recognized that hospitals were grappling with intricate billing processes and revenue cycle inefficiencies. By focusing on developing comprehensive software solutions, Craneware has strategically positioned itself to help these institutions navigate the labyrinth of medical billing and coding. With its suite of services, including charge capture, pricing analytics, and cost management, Craneware aids hospitals in maximizing their revenue and ensuring compliance. This focus allows healthcare providers to transform data into actionable insights, which not only streamlines operations but also enhances fiscal performance. Revenue generation for Craneware comes primarily from its software sales and accompanying support services. The company employs a Software as a Service (SaaS) model, wherein clients subscribe to its offerings on a recurring basis, ensuring a steady inflow of income while fostering long-term business relationships. This model capitalizes on the growing demand for cloud-based solutions, providing clients with the flexibility and scalability required in a constantly evolving healthcare landscape. Craneware’s unique positioning at the intersection of healthcare and financial management means its growth is not just dependent on acquiring new clients, but also on deepening engagements with existing ones, providing upgrades and enhancements that serve the ever-changing needs of the healthcare industry.